Cargando…
Efgartigimod: First Approval
Efgartigimod (efgartigimod alfa-fcab, Vyvgart(™)) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855644/ https://www.ncbi.nlm.nih.gov/pubmed/35179720 http://dx.doi.org/10.1007/s40265-022-01678-3 |